Senti Biosciences, Inc. (NASDAQ:SNTI – Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 43,200 shares, a decline of 70.6% from the June 30th total of 147,000 shares. Based on an average daily volume of 711,600 shares, the short-interest ratio is currently 0.1 days. Currently, 1.6% of the shares of the company are short sold.
Senti Biosciences Price Performance
Shares of NASDAQ:SNTI traded up $0.05 on Thursday, hitting $2.32. The company had a trading volume of 12,206 shares, compared to its average volume of 331,671. Senti Biosciences has a 1-year low of $2.11 and a 1-year high of $10.90. The stock has a 50 day moving average price of $3.03 and a 200 day moving average price of $3.67.
Senti Biosciences (NASDAQ:SNTI – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($2.60) EPS for the quarter. Equities analysts expect that Senti Biosciences will post -10 earnings per share for the current year.
Hedge Funds Weigh In On Senti Biosciences
About Senti Biosciences
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Featured Stories
- Five stocks we like better than Senti Biosciences
- ETF Screener: Uses and Step-by-Step Guide
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Industrial Products Stocks Investing
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.